Depression

Depression in Primary Care: Role and Relevance

Major Depressive Disorder (MDD) is one of the most common and disabling conditions encountered in primary care settings. ^[1] As a Family Nurse Practitioner (FNP), you are often the first point of contact for diagnosis and management. The United States Preventive Services Task Force (USPSTF) recommends screening for depression in the general adult population, including pregnant and postpartum individuals. ^[2]

• Exam Focus: FNPs must master screening, pharmacological management, monitoring for side effects, and suicide risk assessment.
• Clinical Relevance: Failure to diagnose or adequately treat MDD leads to significant morbidity, worsening of chronic medical conditions, and increased healthcare costs.

Core Diagnostic Terms for Depressive Disorders

Core Terminology

• Major Depressive Disorder (MDD): Defined by one or more discrete major depressive episodes (MDE) lasting at least 2 weeks without a history of mania or hypomania.
• Persistent Depressive Disorder (Dysthymia): A chronic, low-grade depressed mood that lasts for at least 2 years (1 year in children/adolescents).
• Anhedonia: A core symptom of MDD; the loss of interest or pleasure in almost all activities.
• Treatment-Resistant Depression (TRD): Failure to achieve remission after two or more adequate trials of antidepressants from different pharmacologic classes. ^[3]
• Remission: The goal of treatment; defined as the absence of depressive symptoms for at least 2 weeks.

Biopsychosocial Factors in Depression Pathophysiology

The Biopsychosocial Model

Depression is not simply a "chemical imbalance." The FNP must understand the interplay of biological, psychological, and social factors for effective treatment planning.

• Monoamine Hypothesis: Dysregulation of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) in the limbic system and prefrontal cortex. ^[4]
• HPA Axis Dysregulation: Chronic stress leads to elevated cortisol levels, which can damage hippocampal neurons and worsen mood regulation.
• Neurotrophic Hypothesis: Reduced Brain-Derived Neurotrophic Factor (BDNF) contributes to hippocampal atrophy.
• Genetic Vulnerability: Heritability is approximately 40-50%. First-degree relatives of individuals with MDD have a 2-4x increased risk.

Recognizing Major Depressive Episodes: DSM-5-TR Criteria

DSM-5-TR Criteria for MDD

To diagnose a major depressive episode, the patient must have 5 or more of the following symptoms present during the same 2-week period, representing a change from previous functioning. ^[5]

Must include: Depressed mood OR Anhedonia.

• Sleep disturbance (insomnia or hypersomnia)
• Interest/pleasure loss (anhedonia)
• Guilt (feelings of worthlessness or excessive guilt)
• Energy loss (fatigue)
• Concentration difficulty (indecisiveness)
• Appetite changes (weight loss or gain)
• Psychomotor changes (agitation or retardation)
• Suicidal ideation (thoughts of death, suicide attempt, or plan)

Memory Aid: "SIG E CAPS" (mnemonic for the 9 criteria).

Exclusion: Symptoms must not be due to a substance (e.g., alcohol, cocaine, prescribed steroids) or another medical condition (e.g., hypothyroidism).

Screening, Differential Diagnosis, and Risk Assessment

Screening Tools

Differential Diagnosis

• Medical Causes: Hypothyroidism, Vitamin D/B12 deficiency, anemia, sleep apnea, chronic pain, substance use disorder.
• Psychiatric Causes: Bipolar disorder (screening is MANDATORY before starting an antidepressant), grief, adjustment disorder, anxiety disorders.

Suicide Risk Assessment

Critical Safety Step: Ask every depressed patient directly about suicidal thoughts. A validated tool like the Columbia-Suicide Severity Rating Scale (C-SSRS) is recommended. ^[6]

• High Risk Factors: Male gender, older age, access to lethal means (firearms), history of prior attempts, substance use, psychosis, hopelessness.
• Action: If acute risk is identified, do not leave the patient alone. Arrange immediate psychiatric evaluation or hospitalization.

Stepped Care and Pharmacologic Approaches to Depression

Stepped Care Model (APA & STAR*D Trial Evidence)

The landmark STAR*D Trial provided evidence for sequential treatment strategies. ^[3]

1. Step 1 (First-Line): SSRI (Citalopram, Sertraline, or Escitalopram). Remission rate ~30%.
2. Step 2 (Switch or Augment): If no remission, switch to another SSRI/SNRI or augment with Bupropion or Buspirone.
3. Step 3: Switch to a different class (e.g., SNRI or NDRI) or augment with Lithium or T3.
4. Step 4: Trial of MAOI or combination therapy. Referral to psychiatry.

Pharmacotherapy Overview

Psychotherapy

• Cognitive Behavioral Therapy (CBT): First-line for mild-moderate depression. Highly effective in combination with pharmacotherapy.
• Interpersonal Therapy (IPT): Focuses on role transitions and grief.
• Behavioral Activation: Evidence-based for severe depression; encourages patients to do activities they used to enjoy despite low motivation.

Antidepressant Safety: Black Box Warning and Serotonin Syndrome

FDA Black Box Warning

• Suicidality: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18-24) during the initial treatment phase (first 1-2 months). ^[7]
• Clinical Action: FNP must educate the patient and family to monitor closely for agitation, irritability, or worsening depression.

Serotonin Syndrome

• A potentially life-threatening condition caused by excess serotonin (often due to combining MAOIs with SSRIs/SNRIs, or using multiple serotonergic agents).
• Triad: Mental status changes (confusion, agitation), Autonomic instability (tachycardia, hypertension, hyperthermia), Neuromuscular effects (myoclonus, hyperreflexia, clonus).
• Management: Discontinue serotonergic agents, supportive care, cyproheptadine.

Bipolar Switching

• Antidepressants can trigger a manic episode in undiagnosed bipolar patients. Screen for a personal or family history of mania/hypomania before starting an antidepressant.

Exam-Relevant Clinical Pearls for Depression Care

• First-Line Treatment: SSRI (Sertraline or Escitalopram).
• Best for Sexual Dysfunction: Bupropion, Mirtazapine.
• Best for Insomnia/Weight Loss: Mirtazapine.
• Avoid in Teens/Young Adults: Paroxetine (high side effect profile).
• QTc Prolongation: Citalopram > 40 mg/day (avoid in elderly or those with risk factors).
• STAR*D Trial Takeaway: Approximately 50% of patients will achieve remission by Step 1 or 2. Failure to improve by 4-6 weeks should prompt a dose adjustment or medication switch.
• When to Refer: Treatment-resistant depression (2 failed trials), high suicide risk, bipolar depression, or presence of psychosis.
• Electroconvulsive Therapy (ECT): Gold standard for severe, treatment-resistant, psychotic, catatonic, or suicidal depression.

References & Sources

1. World Health Organization (WHO). Depressive disorder (depression). https://www.who.int/news-room/fact-sheets/detail/depression
2. U.S. Preventive Services Task Force. Screening for Depression in Adults: USPS Task Force Recommendation Statement. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/depression-in-adults-screening
3. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry.https://doi.org/10.1176/ajp.2006.163.11.1905
4. Stahl, S. M. (2021). Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (5th ed.). Cambridge University Press.
5. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
6. The Columbia Lighthouse Project. Columbia-Suicide Severity Rating Scale (C-SSRS). https://suicidepreventionlifeline.org/wp-content/uploads/2016/09/BH_wcmh_ssrs_1_14_10.pdf
7. U.S. Food and Drug Administration (FDA). Suicidality in Children and Adolescents Being Treated with Antidepressant Medications. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications
8. American Psychological Association (APA). Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. https://www.apa.org/depression-guideline